Comparative Efficacy of Oral and Intravenous Cyclophosphamide in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease and Analysis of Its Influencing Factors: A Clinical Trial
International Archives of Allergy and Immunology · 2025
DOI: 10.1159/000547717 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Archives of Allergy and Immunology, 2025. Verfasst von Wei Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Cyclophosphamide, Lung Diseases, Interstitial, Connective Tissue Diseases, Immunosuppressive Agents. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
Connective tissue disease (CTD) commonly affects the lungs, with interstitial lung disease (ILD) as its main complication; although cyclophosphamide (CTX) is the standard immunosuppressant for CTD-ILD, the optimal route of administration (oral vs. intravenous) remains unclear. This research aimed to analyze the efficacy of oral and intravenous CTX in the treatment of CTD-ILD and analysis of its influencing factors.
Methods
The CTX per oral group (PO group) and intravenous infusion of CTX group (IV group) were established. Clinical efficacy, pulmonary function indices, pulmonary high-resolution computed tomography (HRCT) scores, blood gas parameters, 6-min walking distance (6MWD), SGRQ scores, serum levels of Krebs von den Lungen-6 (KL-6), 25-hydroxyvitamin D (25(OH)D), interferon-gamma (IFN-γ), and interleukin-4 (IL-4), and adverse reactions were examined. Relevant factors influencing the clinical efficacy of CTD-ILD were analyzed.
Results
After treatment, patients in the IV group exhibited lower HRCT score, SGRQ scores, and serum levels of KL-6 and IL-4 compared to those in the PO group. Conversely, the IV group had higher levels of forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), diffusion capacity of the lung for carbon monoxide, FEV1/FVC ratio, partial pressure of oxygen, 6MWD, 25(OH)D, and IFN-γ. Higher serum levels of KL-6 and lower levels of 25(OH)D were associated with poorer treatment outcomes.
Conclusion
For patients with CTD-ILD, intravenous infusion of CTX for 12 months demonstrates superior efficacy compared to oral administration, with a lower incidence of adverse reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.
- Department of Rheumatology and Immunology, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.
- Department of Rheumatology and Immunology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China, fengyuan191@163.com.
Zitieren
APA
Liu, W., Huang, Y., Yang, X., Liu, J., Cao, X., & Feng, Y. (2025). Comparative Efficacy of Oral and Intravenous Cyclophosphamide in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease and Analysis of Its Influencing Factors: A Clinical Trial. International Archives of Allergy and Immunology. https://doi.org/10.1159/000547717
Vancouver
Liu W, Huang Y, Yang X, Liu J, Cao X, Feng Y. Comparative Efficacy of Oral and Intravenous Cyclophosphamide in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease and Analysis of Its Influencing Factors: A Clinical Trial. International Archives of Allergy and Immunology. 2025. doi:10.1159/000547717
BibTeX
@article{Liu2025,
author = {Liu, Wei and Huang, Yumin and Yang, Xichao and Liu, Jie and Cao, Xue and Feng, Yuan},
title = {Comparative Efficacy of Oral and Intravenous Cyclophosphamide in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease and Analysis of Its Influencing Factors: A Clinical Trial},
journal = {International Archives of Allergy and Immunology},
year = {2025},
doi = {10.1159/000547717}
}
EUVIMED